2O Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)

Y. Yang; T. Zhou; F. Gao; W. Feng; W. Jiang; L. Huang; Feifei Zhao; L. Chen; M. Ji; J. Zhu; Y. Fang; P. Chen; P. Wang; J. Wu; Z. Li; X. Liu; M. Deng; G. Weng; H. Zhao; L. Zhang

doi:10.1016/j.esmoop.2026.106309

2O Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)

ESMO Open 2026 Open access

Read full text

Authors: Y. Yang, T. Zhou, F. Gao, W. Feng, W. Jiang, L. Huang, Feifei Zhao, L. Chen, M. Ji, J. Zhu, Y. Fang, P. Chen

+8 more

P. Wang, J. Wu, Z. Li, X. Liu, M. Deng, G. Weng, H. Zhao, L. Zhang

DOI: 10.1016/j.esmoop.2026.106309

Cited by: 5

Abstract

Concurrent TP53 mutations are common in EGFRm NSCLC and associated with poor outcomes to EGFR-TKIs monotherapy. While the FLAURA2 study demonstrated superior efficacy of osi plus CTx in advanced EGFRm NSCLC, whether those with TP53 co-mutations could derive more benefit from combination therapy remains unclear. This randomized, multicenter, phase III trial addresses this critical gap by assessing the efficacy of combination therapy in this high-risk population.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies HER2/EGFR in Cancer Research

Publication details

Journal / source: ESMO Open
Publisher: Elsevier BV
Volume: 11
Pages: 106309–106309
Publication date: 17 March 2026
Language: EN